HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 12, 2008, Pages 4796-4801

  Li, Nainong ^a,b   Zhao, Dongchang ^a   Kirschbaum, Mark ^a   Zhang, Chunyan ^a   Lin, Chia Lei ^a   Todorov, Ivan ^a   Kandeel, Fouad ^a   Forman, Stephen ^a   Zeng, Defu ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Anti CD3 mAB; Graft versus host disease; Hematopoietic cell transplantation; Suberoylanilide hydroxamic acid; Systemic lupus erythematosus

Indexed keywords

CD3 ANTIBODY; CYTOKINE; VORINOSTAT; CD3 ANTIGEN; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CD8+ T LYMPHOCYTE; CHIMERA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE STORM SYNDROME; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; AGING; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; PATHOLOGY; T LYMPHOCYTE;

MUS;

AGING; ANIMALS; ANTIGENS, CD3; APOPTOSIS; CELL PROLIFERATION; CHIMERISM; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 42449130607     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712051105     Document Type: Article

References (31)

1. Sullivan KM (2004) in Thomas' Hematopoietic Cell Transplantation, ed Blume KG, Forman SJ, Appelbaum FR (Blackwell, Malden, MA), pp 635-664.
2. Sykes M, Nikolic B (2005) Treatment of severe autoimmune disease by stem-cell transplantation. Nature 435:620-627.
3. Shizuru J (2004) in Thomas' Hematopoietic Cell Transplantation, ed Blume KG, Forman SJ, Appelbaum FR (Blackwell, Malden, MA), pp 324-343.
4. Ferrara J, Antin. J (2004) in Thomas' Hematopoietic Cell Transplantation, ed Blume KG, Forman SJ, Appelbaum FR (Blackwell, Malden, MA), pp 353-368.
5. Shlomchik WD, et al. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412-415.
6. Teshima T, et al. (2002) Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8:575-581.
7. Chakraverty R, et al. (2006) An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 203:2021-2031.
8. Wekerle T, et al. (2000) Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6:464-469.
9. + T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 105:2180-2188.
10. + T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody. J Immunol 178:838-850.
11. Zhang C, et al. (2007) Elimination of insulitis and augmentation of islet β cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci USA 104:2337-2342.
12. Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81-120.
13. Marks P, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202.
14. Marks PA, Miller T, Richon VM (2003) Histone deacetylases. Curr Opin Pharmacol 3:344-351.
15. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 26:5541-5552.
16. Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99:2995-3000.
17. Reddy P, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101:3921-3926.
18. Leng C, et al. (2006) Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 34:776-787.
19. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111:539-552.
20. Alegre M, et al. (1990) Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol 20:707-710.
21. Smith-Berdan S, Gille D, Weissman IL, Christensen JL (2007) Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood 110:1370-1378.
22. + T cell responses. BMC Cancer 3:30.
23. Dong C (2006) Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol 6:329-333.
24. Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345-350.
25. Rodriguez R, et al. (2004) Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 33:1123-1129.
26. Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13:1299-1307.
27. Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109:1123-1130.
28. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196:389-399.
29. Zeng D, Lee MK, Tung J, Brendolan A, Strober S (2000) Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 164:5000-5004.
30. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S (2003) Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 112:1211-1222.
31. Morris ES, et al. (2005) NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 115:3093-3103.